LT2898885T - Pirolopirimidino dariniai, skirti naudoti virusinių infekcijų gydymui - Google Patents

Pirolopirimidino dariniai, skirti naudoti virusinių infekcijų gydymui

Info

Publication number
LT2898885T
LT2898885T LTEP14198125.8T LT14198125T LT2898885T LT 2898885 T LT2898885 T LT 2898885T LT 14198125 T LT14198125 T LT 14198125T LT 2898885 T LT2898885 T LT 2898885T
Authority
LT
Lithuania
Prior art keywords
treatment
viral infections
pyrrolopyrimidine derivatives
pyrrolopyrimidine
derivatives
Prior art date
Application number
LTEP14198125.8T
Other languages
English (en)
Inventor
Shanta Bantia
Pravin L Kotian
Yarlagadda S Babu
Original Assignee
Biocryst Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharmaceuticals, Inc. filed Critical Biocryst Pharmaceuticals, Inc.
Publication of LT2898885T publication Critical patent/LT2898885T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEP14198125.8T 2010-10-15 2011-10-14 Pirolopirimidino dariniai, skirti naudoti virusinių infekcijų gydymui LT2898885T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39352210P 2010-10-15 2010-10-15
US201161492054P 2011-06-01 2011-06-01

Publications (1)

Publication Number Publication Date
LT2898885T true LT2898885T (lt) 2018-02-26

Family

ID=45938737

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14198125.8T LT2898885T (lt) 2010-10-15 2011-10-14 Pirolopirimidino dariniai, skirti naudoti virusinių infekcijų gydymui

Country Status (24)

Country Link
US (6) US20130331404A1 (lt)
EP (3) EP2898885B1 (lt)
JP (2) JP5902698B2 (lt)
KR (1) KR101850925B1 (lt)
CN (1) CN103429245B (lt)
AU (2) AU2011315902B2 (lt)
BR (1) BR112013009029B1 (lt)
CA (1) CA2813783C (lt)
CY (1) CY1119880T1 (lt)
DK (2) DK2898885T3 (lt)
ES (2) ES2536831T3 (lt)
HK (2) HK1212914A1 (lt)
HR (2) HRP20150487T1 (lt)
HU (1) HUE036387T2 (lt)
IL (1) IL225672B (lt)
LT (1) LT2898885T (lt)
MX (1) MX348759B (lt)
PL (2) PL2627334T3 (lt)
PT (2) PT2627334E (lt)
RS (2) RS54072B1 (lt)
RU (3) RU2599013C2 (lt)
SI (2) SI2627334T1 (lt)
SM (1) SMT201500148B (lt)
WO (1) WO2012051570A1 (lt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP3076A (en) 2008-04-23 2014-12-31 Gilead Sciences Inc Carba-nucleoside analogs for antiviral treatment
PL2480559T3 (pl) 2009-09-21 2013-11-29 Gilead Sciences Inc Sposoby i związki pośrednie do wytwarzania analogów 11cyjanokarbanukleozydowych
PE20130807A1 (es) 2010-07-19 2013-07-27 Gilead Sciences Inc Metodos para la preparacion de profarmacos de fosforamidato diastereomericamente puros
KR101821680B1 (ko) 2010-07-22 2018-01-24 길리애드 사이언시즈, 인코포레이티드 파라믹소비리대 바이러스 감염을 치료하기 위한 방법 및 화합물
WO2012051570A1 (en) 2010-10-15 2012-04-19 Shanta Bantia Methods and compositions for inhibition of polymerase
AR090699A1 (es) * 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
EP3251674A3 (en) * 2012-11-16 2018-02-21 BioCryst Pharmaceuticals, Inc. Antiviral azasugar-containing nucleosides
CA2911424C (en) 2013-05-14 2021-11-30 Biocryst Pharmaceuticals, Inc. Anti-influenza imino-ribose pyrrolopyrimidine derivatives
TWI678369B (zh) * 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
TWI740546B (zh) 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
CN104513249B (zh) * 2014-12-26 2016-08-31 苏州明锐医药科技有限公司 抗埃博拉病毒药物bcx4430的制备方法
MA52371A (fr) 2015-09-16 2021-09-22 Gilead Sciences Inc Méthodes de traitement d'infections dues aux coronaviridae
TWI767903B (zh) * 2016-03-06 2022-06-21 美商百歐克斯製藥公司 用於治療茲卡病毒感染之方法及組合物
DE102016002873A1 (de) 2016-03-09 2016-05-25 Heinz Kiefer Zellnachweisverfahren und Screeningverfahren von Stoffbibliotheken zur Identifizierung von Einzelstoffen, die im Falle einer bioterroristischen Bedrohung gegen Mischungen synthetischer Viren wirksam sind
TW201836615A (zh) 2017-03-14 2018-10-16 美商基利科學股份有限公司 治療貓冠狀病毒感染之方法
KR20190141747A (ko) 2017-05-01 2019-12-24 길리애드 사이언시즈, 인코포레이티드 (S)-2-에틸부틸 2-(((S)-(((2R,3S,4R,5R)-5-(4-아미노피롤로[2,1-f] [1,2,4]트리아진-7-일)-5-시아노-3,4-디히드록시테트라히드로푸란-2-일)메톡시)(페녹시) 포스포릴)아미노)프로파노에이트의 결정질 형태
CN111093627B (zh) 2017-07-11 2024-03-08 吉利德科学公司 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
US20220273689A1 (en) * 2019-07-09 2022-09-01 Regents Of The University Of Minnesota Potentiation of antiviral nucleobases as rna virus therapy
TWI789695B (zh) 2020-01-27 2023-01-11 美商基利科學股份有限公司 治療sars cov-2感染之方法
TWI785528B (zh) 2020-03-12 2022-12-01 美商基利科學股份有限公司 1’-氰基核苷之製備方法
WO2021207049A1 (en) 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
US20230158054A1 (en) * 2020-04-07 2023-05-25 Biocryst Pharmaceuticals, Inc. Methods, compositions, and dosing regimens for treatment of sars-cov-2 infections
CA3179226A1 (en) 2020-05-29 2021-12-02 Tomas Cihlar Remdesivir treatment methods
US11939347B2 (en) 2020-06-24 2024-03-26 Gilead Sciences, Inc. 1′-cyano nucleoside analogs and uses thereof
KR20230057411A (ko) 2020-08-27 2023-04-28 길리애드 사이언시즈, 인코포레이티드 바이러스 감염 치료를 위한 화합물 및 방법
EP4360629A1 (en) * 2021-06-25 2024-05-01 Industry Foundation of Chonnam National University Pharmaceutical composition comprising lipase inhibitor for treatment or treatment of rna viral infections
WO2023023469A1 (en) * 2021-08-17 2023-02-23 Southwest Research Institute Inhibitors for coronavirus
EP4320128A1 (en) 2022-03-02 2024-02-14 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9520364D0 (en) * 1995-10-05 1995-12-06 Chiroscience Ltd Compouundds
US5985848A (en) 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
US6228741B1 (en) 1998-01-13 2001-05-08 Texas Instruments Incorporated Method for trench isolation of semiconductor devices
US7388002B2 (en) 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
US7098334B2 (en) * 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
WO2003100009A2 (en) * 2002-05-23 2003-12-04 Biocryst Pharmaceuticals, Inc. Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof
US7560434B2 (en) * 2004-06-22 2009-07-14 Biocryst Pharmaceuticals, Inc. AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
CA2602533A1 (en) * 2005-03-29 2006-10-05 Biocryst Pharmaceuticals, Inc. Use of c-nucleoside analogs for treatment of hepatitis c related viral infections
US20090227637A1 (en) * 2005-12-15 2009-09-10 Olaf Weber Diaryl ureas for treating virus infections
EP2395005A1 (en) 2006-09-07 2011-12-14 Industrial Research Limited Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases
EP2061316A4 (en) 2006-09-11 2011-08-24 Southern Res Inst AZOL NUCLEOSIDES AND USE AS HEMMER VARIABLE RNA AND DNA POLYMERASES
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
WO2012051570A1 (en) 2010-10-15 2012-04-19 Shanta Bantia Methods and compositions for inhibition of polymerase
EP2638007A2 (en) * 2010-11-11 2013-09-18 Redx Pharma Limited Drug derivatives
AR090699A1 (es) * 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral

Also Published As

Publication number Publication date
RS56870B1 (sr) 2018-04-30
SI2898885T1 (en) 2018-03-30
HUE036387T2 (hu) 2018-07-30
JP5902698B2 (ja) 2016-04-13
SMT201500148B (it) 2015-09-07
KR20140040676A (ko) 2014-04-03
WO2012051570A1 (en) 2012-04-19
US10022375B2 (en) 2018-07-17
HRP20150487T1 (hr) 2015-08-28
CN103429245B (zh) 2016-10-05
BR112013009029B1 (pt) 2021-06-29
JP2013544788A (ja) 2013-12-19
PT2627334E (pt) 2015-07-07
KR101850925B1 (ko) 2018-04-20
BR112013009029A2 (pt) 2018-06-19
EP2627334B1 (en) 2015-04-29
AU2011315902A1 (en) 2013-05-30
RS54072B1 (en) 2015-10-30
AU2017200471A1 (en) 2017-02-23
MX2013003938A (es) 2013-07-05
US20130331404A1 (en) 2013-12-12
US11173159B2 (en) 2021-11-16
AU2011315902B2 (en) 2016-11-17
PT2898885T (pt) 2018-02-05
PL2627334T3 (pl) 2015-08-31
PL2898885T3 (pl) 2018-04-30
US20180360836A1 (en) 2018-12-20
RU2016134401A (ru) 2018-12-10
IL225672B (en) 2019-02-28
US9492452B2 (en) 2016-11-15
CN103429245A (zh) 2013-12-04
SI2627334T1 (sl) 2015-08-31
EP2898885B1 (en) 2017-11-22
IL225672A0 (en) 2013-06-27
CA2813783C (en) 2019-01-22
EP2898885A1 (en) 2015-07-29
EP3345605B1 (en) 2019-11-20
RU2013121794A (ru) 2014-11-20
US20150051230A1 (en) 2015-02-19
US20220040190A1 (en) 2022-02-10
DK2627334T3 (en) 2015-05-18
RU2599013C2 (ru) 2016-10-10
EP2627334A4 (en) 2014-04-16
RU2718690C2 (ru) 2020-04-13
RU2016134401A3 (lt) 2020-01-24
MX348759B (es) 2017-06-28
AU2017200471B2 (en) 2018-04-12
US10420769B2 (en) 2019-09-24
ES2657687T3 (es) 2018-03-06
HRP20180220T1 (hr) 2018-03-09
ES2536831T3 (es) 2015-05-29
EP3345605A1 (en) 2018-07-11
EP2627334A1 (en) 2013-08-21
HK1212914A1 (zh) 2016-06-24
CY1119880T1 (el) 2018-06-27
US20170042901A1 (en) 2017-02-16
RU2020111042A (ru) 2021-09-17
US20190374544A1 (en) 2019-12-12
JP2016135790A (ja) 2016-07-28
HK1257363A1 (zh) 2019-10-18
DK2898885T3 (en) 2018-02-05
CA2813783A1 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
HUE036387T2 (hu) Pirrolopirimidin származékok vírusfertõzések kezelésében való felhasználásra
HK1256490A1 (zh) 用於治療病毒感染的嘧啶衍生物
HRP20181497T1 (hr) Derivati purina za liječenje virusnih infekcija
ZA201500921B (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diaseases
PL2521562T3 (pl) Ev576 do zastosowania w leczeniu zakażeń wirusowych dróg oddechowych
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
PL2903608T3 (pl) Kompozycja farmaceutyczna obejmująca kwas propionowy do stosowania w leczeniu infekcji wirusowych
ZA201306342B (en) The treatment of viral infections
ZA201308025B (en) The use of secnidazole in treating dental infections
GB201001821D0 (en) Treatment of viral infections